Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update

- Commenced market launch and first commercial sales of Symvess™ (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma -

- Total revenues of $517,000 for quarter from sales and collaborative research agreement –

Read more at globenewswire.com